ArticleProceedings of the National Academy of Sciences of the United States of America2012
Fighting malaria with engineered symbiotic bacteria from vector mosquitoes.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 164 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
164 citing papers in PubMed, 3 syntheses or guidelines pooled it, 322 citations in OpenAlex.
- Evaluating paratransgenesis using engineered symbiotic bacteria for Plasmodium inhibition in mosquito vectors: A systematic review.PLoS neglected tropical diseases · 2026Pooled it
- The mosquito gut microbiome andFrontiers in cellular and infection microbiology · 2026Pooled it
- Fungal microbiota diversity inWellcome open research · 2026Pooled it
- Killer bee molecules: antimicrobial peptides as effector molecules to target sporogonic stages of Plasmodium.PLoS pathogens · 2013Trial
- Advances in mosquito gut microbiota: Mechanisms of regulating pathogen transmission and applications in vector control.Virulence · 2026Review
- Mosquito-based malaria control through genetic, microbial and immunological innovations.Nature reviews. Microbiology · 2026Review
- Identifying Transgenic Approaches to Mitigate Vector Transmission of Malaria by Anopheles gambiae.Cureus · 2026Review
- Construction and Evaluation of EngineeredInternational journal of molecular sciences · 2026Article
- Advancing Malaria Vector Control: Insights Into Mosquito Immunity and Genetic Strategies.TheScientificWorldJournal · 2026Review
- Fibrinolysis-unrelated functions of the plasminogen/plasmin system: A gateway to successful parasitism?Current research in parasitology & vector-borne diseases · 2026Review
- Ecological and engineered modulation of the mosquito microbiome: mechanisms, vector competence, and translational prospects for disease control.Frontiers in microbiology · 2026Review
- Environmental persistence and transmission dynamics ofApplied and environmental microbiology · 2025Article
- Molecular characterization of potential Plasmodium-Blocking Serratia spp. bacteria in field-caught malaria mosquito in Burkina Faso.Parasites & vectors · 2025Article
- Exploiting nectar and blood feeding cues and phagostimulants to optimise Attractive Targeted Sugar Baits against a sand fly vector of leishmaniasis.PLoS neglected tropical diseases · 2025Article
- Systemic infection with insect-specific viruses does not affect Plasmodium sporozoite formation in Anopheles mosquitoes.PLoS neglected tropical diseases · 2025Article
- A catalog of proteins released fromMicrobiology spectrum · 2025Article
- Schistosome species, parasite development, and co-infection combinations determine microbiome dynamics in the snail Biomphalaria glabrata.Animal microbiome · 2025Article
- Compatibility ofTropical medicine and infectious disease · 2025Article
- Emerging challenges for mosquito-borne disease control and the promise of symbiont-based transmission-blocking strategies.PLoS pathogens · 2025Review
- Influence of genetic factors of humans, mosquitoes and parasites, on the evolution of Plasmodium falciparum infections, malaria transmission and genetic control methods: a review of the literature.BMC medical genomics · 2025Review
104 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The most vulnerable stages of Plasmodium development occur in the lumen of the mosquito midgut, a compartment shared with symbiotic bacteria. Here, we describe a strategy that uses symbiotic bacteria to deliver antimalaria effector molecules to the midgut lumen, thus rendering host mosquitoes refractory to malaria infection. The Escherichia coli hemolysin A secretion system was used to promote the secretion of a variety of anti-Plasmodium effector proteins by Pantoea agglomerans, a common mosquito symbiotic bacterium. These engineered P. agglomerans strains inhibited development of the human malaria parasite Plasmodium falciparum and rodent malaria parasite Plasmodium berghei by up to 98%. Significantly, the proportion of mosquitoes carrying parasites (prevalence) decreased by up to 84% for two of the effector molecules, scorpine, a potent antiplasmodial peptide and (EPIP)(4), four copies of Plasmodium enolase-plasminogen interaction peptide that prevents plasminogen binding to the ookinete surface. We demonstrate the use of an engineered symbiotic bacterium to interfere with the development of P. falciparum in the mosquito. These findings provide the foundation for the use of genetically modified symbiotic bacteria as a powerful tool to combat malaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.